Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.1.2.13 (aldolase)
 3,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A comparison of preoperative serum tumor markers (lactate dehydrogenase, lactate dehydrogenase isoenzymes, alpha-hydroxybutyrate dehydrogenase, alkaline phosphatase, aldolase, leucine aminopeptidase, cholinesterase, erythrocyte sedimentation reaction, carcinoembryonic antigen, alpha-fetoprotein, and beta 2-microglobulin) was made in 76 patients with ovarian or uterine cancer. Sixty-six patients with benign ovarian tumor served as control subjects. From analysis of each tumor marker the greatest positive results were obtained with the markers beta 2-microglobulin (57.1%), lactate dehydrogenase (53.1%), and hydroxybutyrate dehydrogenase (46.2%) for patients with carcinoma of the ovary. The use of these marker combinations in all ovarian cancer patients resulted in a marked increase of the positive rate from 57.1 to 85.2%. In stage I cases, the positive rate increased from 40.6 to 63.6%.
 ...
PMID:Significance of serum tumor markers in patients with carcinoma of the ovary. 619 5

A comparison of several serum tumor markers (lactate dehydrogenase (LDH), LDH isozyme, hydroxybutylrate dehydrogenase (HBD), alkaline phosphatase (ALP), cholinesterase (Choline-E), aldolase (ALD), leucine aminopeptidase (LAP), gamma-glutamyl transpeptidase (gamma-GTP), human chorionic gonadotropin (HCG), carcinoembryonic antigen (CEA) and alpha 1-fetoprotein (AFP)) was made in patients with carcinoma or benign tumor of the ovary and healthy control subjects. The greatest positive rates were obtained with the markers HBD (76.5%) and Choline-E (73.3%) for patients with carcinoma of the ovary, respectively. However, based on false positive results, Choline-E was also greatest (50.0%) for patients with benign tumor of the ovary. The lowest false positive rates were obtained with ALD, but the positive rates for patients with stage I and II diseases were 0.0%. The most suitable single marker for patients with stage I and II diseases was HBD (62.5%), followed by LDH (41.7%). Three of 4 patients with early cancer, who had normal serum LDH levels, showed abnormal LDH isozyme patterns (elevated LDH-4 and -5). A combination of LDH activity and LDH isozyme resulted in an increase in the positive results (41.7% to 70.0%), that is, the cancer patients were positive for one of the two markers. For CEA, AFP and HCG, the positive results were 26.9%, 19.0% and 7.1%, respectively. Positive and false positive rates for ALP were 36.7% and 7.1%, but the positive rates in the early stage were lower (14.3%), compared to those for LDH and HBD. HBD and LDH activities in the ovarian malignant tissues and ascitic fluids were significantly higher than those in the benign tumor tissues and ascitic fluids, resulting in a significant elevation of serum LDH and HBD levels in the patients. Moreover, it was suggested that inhibition test of ALP by the inhibitors might be able to identify the tissue origin of ALP in the cancer patients.
 ...
PMID:[Diagnostic value of biochemical tumor markers in serum of patients with cancer of the ovary]. 683 10